Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1631
    +0.0020 (+0.17%)
     

  • GBP/USD

    1.2536
    +0.0012 (+0.10%)
     

  • Bitcoin GBP

    48,556.48
    -1,136.83 (-2.29%)
     

  • CMC Crypto 200

    1,260.73
    -97.28 (-7.16%)
     

  • S&P 500

    5,216.64
    +2.56 (+0.05%)
     

  • DOW

    39,491.90
    +104.14 (+0.26%)
     

  • CRUDE OIL

    78.54
    -0.72 (-0.91%)
     

  • GOLD FUTURES

    2,370.10
    +29.80 (+1.27%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

How Important Is Novavax's COVID Vaccine Manufacturing Deal With GlaxoSmithKline?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·3-min read

GlaxoSmithKline (NYSE: GSK) has teamed up with several other companies to develop COVID-19 vaccine candidates. In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how important this manufacturing deal with GlaxoSmithKline is for Novavax. Keith Speights: Novavax -- the ticker there is NVAX -- announced this week that it's teamed up with GlaxoSmithKline -- ticker there is GSK -- to support the manufacturing of its COVID vaccine in the United Kingdom.

Continue reading